Stock Buzzer: What’s Ahead for Vitae Pharmaceuticals Inc After Achieving 52-Week High?

Stock Buzzer: What's Ahead for Vitae Pharmaceuticals Inc After Achieving 52 Week High?

The stock of Vitae Pharmaceuticals Inc (NASDAQ:VTAE) hit a new 52-week high and has $26.42 target or 26.00% above today’s $20.97 share price. The 5 months bullish chart indicates low risk for the $604.80M company. The 1-year high was reported on Sep, 30 by Barchart.com. If the $26.42 price target is reached, the company will be worth $157.25M more.
The 52-week high event is an important milestone for every stock because it shows very positive momentum and is time when buyers come in. During such notable technical setup, fundamental investors usually stay away and are careful shorting or selling the stock. About 310,020 shares traded hands. Vitae Pharmaceuticals Inc (NASDAQ:VTAE) has risen 128.49% since February 26, 2016 and is uptrending. It has outperformed by 118.07% the S&P500.

Analysts await Vitae Pharmaceuticals Inc (NASDAQ:VTAE) to report earnings on November, 3. They expect $-0.42 earnings per share, up 30.00% or $0.18 from last year’s $-0.6 per share. After $-0.37 actual earnings per share reported by Vitae Pharmaceuticals Inc for the previous quarter, Wall Street now forecasts 13.51% negative EPS growth.

Vitae Pharmaceuticals Inc (NASDAQ:VTAE) Ratings Coverage

Out of 5 analysts covering Vitae Pharmaceuticals (NASDAQ:VTAE), 2 rate it a “Buy”, 0 “Sell”, while 3 “Hold”. This means 40% are positive. Vitae Pharmaceuticals has been the topic of 7 analyst reports since August 8, 2015 according to StockzIntelligence Inc. On Thursday, September 15 the stock rating was downgraded by Wells Fargo to “Market Perform”. The stock of Vitae Pharmaceuticals Inc (NASDAQ:VTAE) has “Neutral” rating given on Wednesday, September 21 by Piper Jaffray. The rating was upgraded by Stifel Nicolaus on Thursday, March 17 to “Buy”. The stock of Vitae Pharmaceuticals Inc (NASDAQ:VTAE) earned “Market Perform” rating by JMP Securities on Thursday, August 4. Wells Fargo initiated Vitae Pharmaceuticals Inc (NASDAQ:VTAE) on Friday, December 4 with “Outperform” rating. Zacks upgraded Vitae Pharmaceuticals Inc (NASDAQ:VTAE) on Saturday, August 8 to “Sell” rating. The rating was initiated by BMO Capital Markets with “Outperform” on Tuesday, April 12.

According to Zacks Investment Research, “Vitae Pharmaceuticals, Inc. is a clinical stage biotechnology company. It is focused on discovering and developing small molecule drugs for diseases. The Company addresses multiple disease areas including diabetes, Alzheimer’s disease, autoimmune disorders, atopic dermatitis, and acute coronary syndrome. Its product candidates include VTP-34072, which is in a Phase II clinical trial for the treatment of type 2 diabetes; and VTP-37948 that is in Phase I clinical trials for Alzheimer’s disease. Vitae Pharmaceuticals, Inc. is headquartered in Fort Washington, Pennsylvania.”

Insitutional Activity: The institutional sentiment increased to 1.92 in Q2 2016. Its up 0.56, from 1.36 in 2016Q1. The ratio is positive, as 14 funds sold all Vitae Pharmaceuticals Inc shares owned while 11 reduced positions. 11 funds bought stakes while 37 increased positions. They now own 20.80 million shares or 5.46% more from 19.72 million shares in 2016Q1.
Voya Invest Management Llc owns 12,101 shares or 0% of their US portfolio. Price T Rowe Inc Md has invested 0% of its portfolio in Vitae Pharmaceuticals Inc (NASDAQ:VTAE). Bvf Il holds 761,079 shares or 1.75% of its portfolio. Int Group reported 15,136 shares or 0% of all its holdings. Blackrock Institutional Tru Na last reported 0% of its portfolio in the stock. Awm Investment has 2.72% invested in the company for 1.18 million shares. California State Teachers Retirement Systems has 0% invested in the company for 55,134 shares. Citadel Limited Liability Company has 17,574 shares for 0% of their US portfolio. Clarivest Asset Mgmt Limited Company last reported 68,036 shares in the company. Retail Bank Of America De holds 0% or 2,203 shares in its portfolio. Dimensional Fund Limited Partnership has 68,016 shares for 0% of their US portfolio. Millennium Limited Liability holds 0.01% of its portfolio in Vitae Pharmaceuticals Inc (NASDAQ:VTAE) for 336,463 shares. Bridgeway Cap Mgmt accumulated 60,350 shares or 0.01% of the stock. Teachers Advisors last reported 41,690 shares in the company. Bnp Paribas Arbitrage Sa has 0% invested in the company for 1,025 shares.

Insider Transactions: Since September 14, 2016, the stock had 0 buys, and 2 selling transactions for $22.41 million net activity. 50,000 Vitae Pharmaceuticals Inc (NASDAQ:VTAE) shares with value of $1.04M were sold by Hatfield Jeffrey S.. On Wednesday, September 14 the insider ADAGE CAPITAL PARTNERS GP – L.L.C. sold $21.37M.

More notable recent Vitae Pharmaceuticals Inc (NASDAQ:VTAE) news were published by: Fool.com which released: “Here’s Why Shares of Vitae Pharmaceuticals Inc Are Skyrocketing Today” on September 14, 2016, also Prnewswire.com with their article: “Harwood Feffer LLP Announces Investigation of Vitae Pharmaceuticals, Inc.” published on September 14, 2016, Prnewswire.com published: “VITAE SHAREHOLDER NOTICE: Faruqi & Faruqi, LLP Announces the Investigation of …” on September 23, 2016. More interesting news about Vitae Pharmaceuticals Inc (NASDAQ:VTAE) were released by: Marketwatch.com and their article: “Allergan to acquire Vitae Pharma in an all-cash deal valued at about $639 million” published on September 14, 2016 as well as Globenewswire.com‘s news article titled: “Vitae Pharmaceuticals to Present at Wells Fargo Healthcare Conference” with publication date: September 01, 2016.

VTAE Company Profile

Vitae Pharmaceuticals, Inc., incorporated on May 21, 2001, is a biotechnology company. The Firm is focused on discovering and developing small molecule drugs for diseases. It is engaged in developing a portfolio of product candidates through Contour, its structure drug discovery platform. The Company’s product candidates include VTP- 43742 for the treatment of psoriasis, as well as multiple other autoimmune disorders. The Firm completed approximately two Phase I studies with VTP-43742. The Company’s VTP-38543, a second product candidate is in a Phase IIa proof-of-concept clinical trial for the treatment of atopic dermatitis. The Company’s VTP-36951 is for the treatment and prevention of Alzheimer’s disease, or Alzheimer’s.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.

Leave a Comment